Cross-reactivity of SARS-CoV-2- and influenza A-specific T cells in individuals exposed to SARS-CoV-2.
Adaptive immunity
COVID-19
Immunology
T cells
Journal
JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073
Informations de publication
Date de publication:
22 09 2022
22 09 2022
Historique:
received:
18
01
2022
accepted:
10
08
2022
entrez:
22
9
2022
pubmed:
23
9
2022
medline:
24
9
2022
Statut:
epublish
Résumé
Cross-reactive immunity between SARS-CoV-2 and other related coronaviruses has been well-documented, and it may play a role in preventing severe COVID-19. Epidemiological studies early in the pandemic showed a geographical association between high influenza vaccination rates and lower incidence of SARS-CoV-2 infection. We, therefore, analyzed whether exposure to influenza A virus (IAV) antigens could influence the T cell repertoire in response to SARS-CoV-2, indicating a heterologous immune response between these 2 unrelated viruses. Using artificial antigen-presenting cells (aAPCs) combined with real-time reverse-transcription PCR (RT-qPCR), we developed a sensitive assay to quickly screen for antigen-specific T cell responses and detected a significant correlation between responses to SARS-CoV-2 epitopes and IAV dominant epitope (M158-66). Further analysis showed that some COVID-19 convalescent donors exhibited both T cell receptor (TCR) specificity and functional cytokine responses to multiple SARS-CoV-2 epitopes and M158-66. Utilizing an aAPC-based stimulation/expansion assay, we detected cross-reactive T cells with specificity to SARS-CoV-2 and IAV. In addition, TCR sequencing of the cross-reactive and IAV-specific T cells revealed similarities between the TCR repertoires of the two populations. These results indicate that heterologous immunity shaped by our exposure to other unrelated endemic viruses may affect our immune response to novel viruses such as SARS-CoV-2.
Identifiants
pubmed: 36134660
pii: 158308
doi: 10.1172/jci.insight.158308
pmc: PMC9675569
doi:
pii:
Substances chimiques
Antigens, Viral
0
Cytokines
0
Epitopes
0
Receptors, Antigen, T-Cell
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIBIB NIH HHS
ID : P41 EB028239
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA108835
Pays : United States
Organisme : NIBIB NIH HHS
ID : R01 EB029341
Pays : United States
Organisme : NCI NIH HHS
ID : R33 CA229042
Pays : United States
Références
Front Immunol. 2020 Oct 16;11:586984
pubmed: 33178220
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
Nano Lett. 2020 Sep 9;20(9):6289-6298
pubmed: 32594746
Int J Infect Dis. 2020 Sep;98:180-186
pubmed: 32562846
Nat Immunol. 2021 Jan;22(1):74-85
pubmed: 32999467
Res Sq. 2020 Aug 04;:
pubmed: 32793896
Immunity. 2005 Jan;22(1):81-92
pubmed: 15664161
Nat Biotechnol. 2020 Oct;38(10):1194-1202
pubmed: 32341563
Cancer Immunol Res. 2018 Feb;6(2):151-162
pubmed: 29263161
Eur J Immunol. 1999 Aug;29(8):2385-91
pubmed: 10458750
Nat Rev Microbiol. 2021 Mar;19(3):141-154
pubmed: 33024307
JCI Insight. 2018 Oct 4;3(19):
pubmed: 30282836
Nat Rev Immunol. 2020 Aug;20(8):457-458
pubmed: 32636479
J Biol Chem. 2012 Jan 6;287(2):1168-77
pubmed: 22102287
Immunity. 2020 Nov 17;53(5):1095-1107.e3
pubmed: 33128877
Cell Rep. 2021 Mar 16;34(11):108863
pubmed: 33691089
Blood. 2009 Nov 5;114(19):4099-107
pubmed: 19706884
J Clin Invest. 2005 Dec;115(12):3602-12
pubmed: 16308574
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Vaccines (Basel). 2021 Apr 24;9(5):
pubmed: 33923159
Nature. 2017 Jul 6;547(7661):94-98
pubmed: 28636589
Nat Commun. 2013;4:2680
pubmed: 24157944
JAMA Netw Open. 2021 Mar 1;4(3):e212816
pubmed: 33688968
J Transl Med. 2003 Aug 14;1(1):3
pubmed: 14527342
Nucleic Acids Res. 2020 Jan 8;48(D1):D1057-D1062
pubmed: 31588507
Expert Rev Vaccines. 2011 Mar;10(3):299-306
pubmed: 21434798
Science. 2020 Nov 27;370(6520):
pubmed: 32994364
Science. 2020 Oct 2;370(6512):89-94
pubmed: 32753554
Immunol Rev. 2010 May;235(1):244-66
pubmed: 20536568
Prev Med. 2021 Feb;143:106351
pubmed: 33275965
J Med Virol. 2021 Jan;93(1):64-65
pubmed: 32497290
Bioinformatics. 2004 Aug 4;20 Suppl 1:i379-85
pubmed: 15262823
Clin Cancer Res. 2020 Mar 15;26(6):1359-1371
pubmed: 31831563
Nat Rev Immunol. 2012 Sep;12(9):669-77
pubmed: 22918468
Nat Cell Biol. 2021 May;23(5):538-551
pubmed: 33972731
Elife. 2021 Nov 30;10:
pubmed: 34845983
Clin Vaccine Immunol. 2009 Jul;16(7):1066-73
pubmed: 19494085
Vaccines (Basel). 2020 Sep 16;8(3):
pubmed: 32947988
J Immunother Cancer. 2021 Jul;9(7):
pubmed: 34230111
Crit Rev Immunol. 2012;32(4):349-72
pubmed: 23237510